medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2006, Número 1

<< Anterior

Ann Hepatol 2006; 5 (1)


Drug induced liver injury secondary to interferon-beta (IFN-β) in multiple sclerosis

Byrnes V, Afdhal N, Challies T, Greenstein PE

Idioma: Ingles.
Referencias bibliográficas: 7
Paginas: 56-59
Archivo PDF: 160.34 Kb.


FRAGMENTO

Sin resumen


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Tremlett HL, Yoshida EM, Oger J. Liver injury associated with the beta-interferons for MS: a comparison between the three products. Neurology 2004; 62: 628-631.

  2. Tremlett HL, Oger J. Elevated aminotransferases during treatment with interferon-beta for multiple sclerosis: actions and outcomes. Mult Scler 2004; 10: 298-301.

  3. Francis GS, Grumser Y, Alteri E, Micaleff A, O’Brien F, Alsop J, Stam Moraga M, et al. Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance. Drug Saf 2003; 26: 815-827.

  4. Jaeschke H, Gores GJ, Cederbaum AI, Hinson JA, Pessayre D, Lemasters JJ. Mechanisms of hepatotoxicity. Toxicol Sci 2002; 65: 166-176.

  5. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 2003; 349: 474-485.

  6. Durelli L, Bongioanni MR, Ferrero B, Oggero A, Marzano A, Rizzetto M. Interferon treatment for multiple sclerosis: autoimmune complications may be lethal. Neurology 1998; 50: 570-571.

  7. Speciale L, Saresella M, Caputo D, Ruzzante S, Mancuso R, Calvo MG, Guerini FR, et al. Serum auto antibodies presence in multiple sclerosis patients treated with beta-interferon 1a and 1b. J Neurovirol 2000; 6 Suppl 2: S57-61.




2020     |     www.medigraphic.com